Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside
出版年份 2017 全文链接
标题
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside
作者
关键词
-
出版物
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 23, Issue 1, Pages 23-37
出版商
SAGE Publications
发表日期
2017-06-01
DOI
10.1177/1074248417708617
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antithrombotic therapy for patients with STEMI undergoing primary PCI
- (2017) Francesco Franchi et al. Nature Reviews Cardiology
- Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
- (2017) William R. Hiatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)
- (2016) David D. Berg et al. AMERICAN JOURNAL OF CARDIOLOGY
- Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery DiseaseCLINICAL PERSPECTIVE
- (2016) Marc P. Bonaca et al. CIRCULATION
- Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionClinical Perspective
- (2016) Erin A. Bohula et al. CIRCULATION
- Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar
- (2016) Marc P. Bonaca et al. JACC-Cardiovascular Interventions
- Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease
- (2016) Davide Capodanno et al. Nature Reviews Cardiology
- Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
- (2016) Stephen K. Kidd et al. Journal of the American Heart Association
- Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
- (2015) M. A. Cavender et al. CIRCULATION
- Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
- (2015) G. Magnani et al. Journal of the American Heart Association
- Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
- (2014) Pierluigi Tricoci et al. AMERICAN HEART JOURNAL
- Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
- (2014) William Schuyler Jones et al. AMERICAN HEART JOURNAL
- Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
- (2014) Marco Valgimigli et al. AMERICAN JOURNAL OF CARDIOLOGY
- Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting About Vorapaxar
- (2014) Nevin C. Baker et al. CIRCULATION
- New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo
- (2014) Marc P. Bonaca et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Vorapaxar, Combination Antiplatelet Therapy, and Stroke∗
- (2014) Robert G. Hart et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Coronary Stent Thrombosis With Vorapaxar Versus Placebo
- (2014) Marc P. Bonaca et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2014) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease
- (2014) G. Rosser et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Novel antiplatelet agents in acute coronary syndrome
- (2014) Francesco Franchi et al. Nature Reviews Cardiology
- Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
- (2013) Kenneth W. Mahaffey et al. AMERICAN JOURNAL OF CARDIOLOGY
- Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents
- (2013) Dominick J. Angiolillo et al. American Journal of Cardiovascular Drugs
- Vorapaxar in Patients With Peripheral Artery Disease
- (2013) Marc P. Bonaca et al. CIRCULATION
- Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial
- (2013) S. Leonardi et al. EUROPEAN HEART JOURNAL
- The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar
- (2013) Teddy Kosoglou et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery
- (2013) David J. Whellan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
- (2013) Yongjun Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
- (2013) Peter Libby NEW ENGLAND JOURNAL OF MEDICINE
- Clopidogrel Added to Aspirin Adds No Benefit but Bleeding Risk in Patients With Recent Lacunar Stroke
- (2013) Hans-Christoph Diener et al. STROKE
- Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
- (2013) David A. Morrow et al. STROKE
- Third Universal Definition of Myocardial Infarction
- (2012) Kristian Thygesen et al. CIRCULATION
- The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes
- (2012) Dominick J. Angiolillo DRUGS
- Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment
- (2012) Paul Statkevich et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
- (2012) Teddy Kosoglou et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
- (2012) Benjamin M Scirica et al. LANCET
- Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events
- (2012) David A. Morrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease
- (2011) Stephen D. Wiviott et al. CIRCULATION
- Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes
- (2011) Michelle L. O'Donoghue et al. CIRCULATION
- Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
- (2011) José Luis Ferreiro et al. CIRCULATION
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
- (2011) Davide Capodanno et al. Circulation-Cardiovascular Interventions
- Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel
- (2011) N. S. KIRKBY et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
- (2011) Pierluigi Tricoci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced Thrombin Generation After Cardiopulmonary Bypass Surgery
- (2010) Susanne Lison et al. ANESTHESIA AND ANALGESIA
- Basic Principles of Platelet Biology and Clinical Implications
- (2010) Dominick J. Angiolillo et al. CIRCULATION JOURNAL
- Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist
- (2010) A. Ghosal et al. DRUG METABOLISM AND DISPOSITION
- Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
- (2010) S. Goto et al. EUROPEAN HEART JOURNAL
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation
- (2010) P. C. J. ARMSTRONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Protease-activated receptors in cardiovascular health and diseases
- (2009) Rahman Shah AMERICAN HEART JOURNAL
- Platelet thrombin receptor antagonism and atherothrombosis
- (2009) D. J. Angiolillo et al. EUROPEAN HEART JOURNAL
- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
- (2009) Richard C Becker et al. LANCET
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell Adhesion Mechanisms in Platelets
- (2008) David Varga-Szabo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity
- (2008) Samuel Chackalamannil et al. JOURNAL OF MEDICINAL CHEMISTRY
- Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
- (2008) David Erlinge et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started